Identifying aggressive prostate cancer at diagnosis using advanced imaging and biomarker techniques
Identifying lethal prostate cancer at diagnosis with advanced proteoglycomic, radiomic, and genomic approaches
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10884411
This study is looking to help doctors find dangerous prostate cancer more accurately when patients are first diagnosed by using new imaging techniques and special tests, so they can better decide on the right treatment for those at higher risk.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10884411 on ClinicalTrials.gov |
What this research studies
This research aims to improve the identification of lethal prostate cancer at the time of diagnosis by utilizing advanced imaging techniques and biomarker analysis. It focuses on enhancing the sensitivity and specificity of magnetic resonance imaging (MRI) through a novel approach called diffusion basis spectral imaging (DBSI), which can detect critical changes in the prostate microenvironment. Additionally, the study investigates specific extracellular proteoglycomic biomarkers associated with aggressive forms of prostate cancer. By accurately identifying high-risk patients, the research seeks to inform treatment decisions and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer who are at risk of developing lethal forms of the disease.
Not a fit: Patients with benign prostate conditions or those with advanced metastatic prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses of aggressive prostate cancer, allowing for timely and effective treatment options.
How similar studies have performed: Previous research has shown promise in using advanced imaging techniques and biomarkers for cancer diagnosis, indicating potential success for this novel approach.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: IPPOLITO, JOSEPH EDWARD — WASHINGTON UNIVERSITY
- Study coordinator: IPPOLITO, JOSEPH EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.